Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics-Reference-Cited by-同舟云学术

Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics

Published:2019-01-02 Issue:1 Volume:42 Page:22-28
ISSN:2578-5826
Container-title:Immunological Medicine
language:en
Short-container-title:Immunological Medicine

Author:

Nishie Wataru¹

Affiliation:

1. Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/25785826.2019.1619233

Reference45 articles.

1. Pemphigoid diseases

2. Update on the pathogenesis of bullous pemphigoid: An autoantibody-mediated blistering disease targeting collagen XVII

3. Humanization of autoantigen

4. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model

5. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. An Urticarial and Acral Manifestation of Bullous Pemphigoid After Vildagliptin Therapy: A Case Report;Cureus;2024-03-27

3. Applying Advanced Practice Nurses in Rural Japan: A Mixed-Methods Perspective;Cureus;2024-03-27

4. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid;International Journal of Molecular Sciences;2023-11-26

5. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid diagnosed by oral manifestation;Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology;2023-11